Skip to main content

Table 2 The hydroxyproline values calculated in the different groups.

From: The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis

 

Group 1

Group 2

Group 1 vs. Group 2

No SOM treatment

Uninf.: 1.06 ± 0.10

Acute: 9.37 ± 0.63

p-value: 0.01**

Chronic: 9.65 ± 0.96

Uninf.: 1.06 ± 0.10

Chronic: 9.65 ± 0.96

p-value: 0.007**

Acute: 9.37 ± 0.63

Chronic: 9.65 ± 0.96

p-value: 0.90 (NS)

1 day SOM treatment

Acute: 9.37 ± 1.24

Uninf.: 0.85 ± 0.08

Chronic: 8.99 ± 0.61

p-value: <0.0001**

Acute: 9.37 ± 1.24

Chronic: 8.99 ± 0.61

p-value: 0.90 (NS)

2 day SOM treatment

Uninf.: 0.81 ± 0.09

Acute: 4.76 ± 0.58

p-value: 0.007**

Acute (untreated): 9.37 ± 0.63

Acute (2d SOM): 4.76 ± 0.58

p-value: 0.01**

Uninf.: 0.93 ± 0.09

Chronic: 5.88 ± 1.13

p-value: 0.02*

Chronic (untreated): 9.65 ± 0.96

Chronic (2d SOM): 5.8 ± 1.13

p-value: 0.03*

Uninf. (17 wks.): 0.81 ± 0.09

Uninf. (21 wks.): 0.93 ± 0.09

p-value: 0.41 (NS)

Acute: 4.76 ± 0.58

Chronic: 5.88 ± 1.13

p-value: 0.41 (NS)

  1. SOM: somatostatin; Uninf.: uninfected; Inf.: infected; Wks.: weeks;
  2. *Significant difference (p < 0.05); ** significant difference (p < 0.01);
  3. NS: not significant difference